Aimmune Therapeutics, Inc. (AIMT) financial statements (2020 and earlier)

Company profile

Business Address 8000 MARINA BOULEVARD
BRISBANE, CA 94005-1884
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:201304182283192
Cash and cash equivalents771087312477
Short-term investments119196109125115
Other undisclosed cash, cash equivalents, and short-term investments5(0)(0)34 
Other undisclosed current assets297(31)6
Total current assets:202313189252197
Noncurrent Assets
Operating lease, right-of-use asset12
Property, plant and equipment292617103
Long-term investments and receivables5  348
Long-term investments5  348
Other undisclosed noncurrent assets11134
Total noncurrent assets:4627184715
TOTAL ASSETS:248340207299212
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities413827115
Accounts payable129512
Accrued liabilities292921103
Debt2    
Other liabilities00000
Total current liabilities:443827115
Noncurrent Liabilities
Long-term debt and lease obligation51    
Long-term debt, excluding current maturities40    
Operating lease, liability11
Liabilities, other than long-term debt13311
Other liabilities13311
Total noncurrent liabilities:523311
Total liabilities:964129136
Stockholders' equity
Stockholders' equity attributable to parent153299178286206
Common stock00000
Additional paid in capital810775443420260
Accumulated other comprehensive income (loss)0(0)(0)(0)(0)
Accumulated deficit(658)(476)(265)(134)(53)
Total stockholders' equity:153299178286206
TOTAL LIABILITIES AND EQUITY:248340207299212

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Operating expenses(241)(215)(133)(82)(36)
Operating loss:(241)(215)(133)(82)(36)
Nonoperating income
(Other Nonoperating income)
  210
Interest and debt expense(0)   (0)
Loss from continuing operations before equity method investments, income taxes:(241)(215)(131)(81)(36)
Other undisclosed income from continuing operations before income taxes35   
Loss from continuing operations before income taxes:(239)(211)(131)(81)(36)
Income tax expense (benefit)0(0)(0) 7
Net loss:(239)(211)(131)(81)(29)
Other undisclosed net loss attributable to parent    (7)
Net loss available to common stockholders, diluted:(239)(211)(131)(81)(36)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(239)(211)(131)(81)(29)
Other comprehensive loss    (0)
Comprehensive loss:(239)(211)(131)(81)(29)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0 (0)0(7)
Comprehensive loss, net of tax, attributable to parent:(238)(211)(131)(81)(36)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: